Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Follow-up Analysis of Ixazomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Routine Clinical Practice

Blood (2021) 138 (Supplement 1): 2716.

https://doi.org/10.1182/blood-2021-148836

Published: 2021

Journal Articles

Overall Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (RD) in RRMM Patients Treated in Routine Clinical Practice: Results from the Czech Registry of Monoclonal Gammopathies (RMG)

Blood (2019) 134 (Supplement_1): 3139.

https://doi.org/10.1182/blood-2019-128865

Published: 2019

Journal Articles

20 Years of Transplant Program in Multiple Myeloma - a Single Centre Experience

Jiri Minarik, MD PhD, Edgar Faber, MD, Ludek Raida, MD PhD, Tomas Szotkowski, MD, Jaroslav Bacovsky, Tomas Pika, MD PhD, Ivana Skoumalova, MD PhD, Petra Krhovska, Jana Zapletalova, Mgr., PhD, Tomas Papajik, MD prof, Vlastimil Scudla, Prof, MD CSc

Blood (2018) 132 (Supplement 1): 5749.

https://doi.org/10.1182/blood-2018-99-112115

Published: 2018

Journal Articles

Treatment of Relapsed and Refractory Multiple Myeloma with Fully Oral Triplet IRD (ixazomib, lenalidomide and dexamethasone) Is Safe and with Significant Therapeutic Outcomes

Blood (2018) 132 (Supplement 1): 1959.

https://doi.org/10.1182/blood-2018-99-112046

Published: 2018

Journal Articles

Single Agent Daratumumab in Advanced Multiple Myeloma: Specific Healthcare Program in the Czech Republic

Jiri Minarik, MD PhD, Ludek Pour, MD PhD, Vladimir Maisnar, Prof, MD PhD, Ivan Spicka, MDPhD, Alexandra Jungova, MD, Hana Plonkova, Lucie Brozova, MSc, Petra Krhovska, Tomas Pika, Jaroslav Bacovsky, Sabina Sevcikova, RNDr, PhD, Jakub Radocha, MD PhD, Vlastimil Scudla, Prof, MD CSc, Roman Hájek, MD

Blood (2017) 130 (Supplement 1): 5414.

https://doi.org/10.1182/blood.V130.Suppl_1.5414.5414

Published: 2017

Journal Articles

Prognostic Value of the Parameters of Myeloma Bone Disease Signaling in Patients with Newly Diagnosed Multiple Myeloma Treated with Proteasome Inhibitors

Jiri Minarik, MD PhD, Zuzana Hermanova, Jan Hrbek, Pavla Petrova, Patrik Flodr, Petra Krhovska, Tomas Pika, Jaroslav Bacovsky, Miroslav Herman, Vlastimil Scudla

Blood (2016) 128 (22): 5603.

https://doi.org/10.1182/blood.V128.22.5603.5603

Published: 2016

Journal Articles

Assessment of the Parameters of Myeloma Bone Disease Signaling to the Extent of Skeletal Involvement, Bone Mineral Turnover and Activity of Multiple Myeloma

Jiri Minarik, Zuzana Hermanova, Pavla Petrova, Jana Zapletalova, Jan Hrbek, Petra Pusciznova, Jaroslav Bacovsky, Tomas Pika, Miroslav Herman, Vlastimil Scudla

Blood (2015) 126 (23): 1754.

https://doi.org/10.1182/blood.V126.23.1754.1754

Published: 2015

Journal Articles

Multiple Myeloma and Bone Marrow Microenvironment Immunohistochemical Study of the Expression of 15 Proteins Related to Myeloma Bone Disease

Patrik Flodr, Pavla Latalova, Petra Pusciznova, Tomas Pika, Jaroslav Bacovsky, Vlastimil Scudla, Jiri Minarik

Blood (2015) 126 (23): 5318.

https://doi.org/10.1182/blood.V126.23.5318.5318

Published: 2015

Journal Articles

Early Diagnosis of Multiple Myeloma - Project CRAB of Czech Myeloma Group(CMG)

Jan Straub, MD, Roman Hajek, Vlastimil Scudla, prof, MD PhD, Vladimir Maisnar, As Prof, MD PhD, Evzen Gregora, Miroslava Schutzova, Zdenek Adam, prof, MD PhD, Jaroslav Bacovsky, MD PhD, Ivan Spicka, Prof. MD PhD

Blood (2014) 124 (21): 5682.

https://doi.org/10.1182/blood.V124.21.5682.5682

Published: 2014

Journal Articles

Subcutaneous and Intravenous Bortezomib in Multiple Myeloma Patients Has Similar Response Rates and Toxicity Profile with No Difference in the Incidence of Peripheral Neuropathy: Report of the Czech Myeloma Group

Blood (2014) 124 (21): 2117.

https://doi.org/10.1182/blood.V124.21.2117.2117

Published: 2014

Journal Articles

Assessment of Signalling Pathways in Myeloma Bone Disease Using Selected Parameters of Bone Marow Microenvironment

Jiri Minarik, MD PhD, Patrik Flodr, MD, Tomas Pika, MD PhD, Jaroslav Bacovsky, MD PhD, Pavla Latalova, MD, Petra Pusciznova, MD, Vlastimil Scudla, prof, MD PhD

Blood (2014) 124 (21): 5679.

https://doi.org/10.1182/blood.V124.21.5679.5679

Published: 2014

Journal Articles

The Use Of Selected Parameters Of Bone Microenvironment For The Assessment Of Skeletal Involvement and Activity In Multiple Myeloma and Monoclonal Gammopathy Of Undetermined Significance

Jiri Minarik, MD, PhD, Petra Pusciznova, MD, Pavla Petrova, MD, Miroslav Herman, prof. MD, Ph.D., Tomas Pika, MD, PhD, Jan Hrbek, MD, Jaroslav Bacovsky, MD, Ph.D., Jana Zapletalova, Vlastimil Scudla, Prof. MD, Ph.D.

Blood (2013) 122 (21): 5339.

https://doi.org/10.1182/blood.V122.21.5339.5339

Published: 2013

Journal Articles

Combined Measurement of Plasma Cell Proliferation and Apoptosis in Multiple Myeloma.

Jiri Minarik, Vlastimil Scudla, Marta Ordeltova, Tomas Pika, Jaroslav Bacovsky, Michael Steinbach, Vipin Kumar, Brian G Van Ness

Blood (2009) 114 (22): 4884.

https://doi.org/10.1182/blood.V114.22.4884.4884

Published: 2009

Journal Articles

Long-Term Outcomes of Autologous Transplantation in Multiple Myeloma: Benefit from the Newer Drugs Used in the Relapsed Setting.

Blood (2008) 112 (11): 3331.

https://doi.org/10.1182/blood.V112.11.3331.3331

Published: 2008

Journal Articles

Angiotensin-I Converting Enzyme Inhibitors and the Survival of Patients with Multiple Myeloma Treated by Autologous Stem Cell Transplantation.

Tomas Buchler, MD, PhD, Marta Krejci, MD, PhD, Adam Svobodnik, PhD, Zdenek Adam, MD, PhD, Jiri Minarik, MD, Jaroslav Bacovsky, MD, PhD, Vlastimil Scudla, MD, PhD, Jiri Mayer, MD, PhD, Jiri Vorlicek, MD, PhD, Roman Hajek, MD, PhD

Blood (2004) 104 (11): 944.

https://doi.org/10.1182/blood.V104.11.944.944

Published: 2004

NARROW

Follow-up Analysis of Ixazomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Routine Clinical Practice

Overall Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (RD) in RRMM Patients Treated in Routine Clinical Practice: Results from the Czech Registry of Monoclonal Gammopathies (RMG)

20 Years of Transplant Program in Multiple Myeloma - a Single Centre Experience

Treatment of Relapsed and Refractory Multiple Myeloma with Fully Oral Triplet IRD (ixazomib, lenalidomide and dexamethasone) Is Safe and with Significant Therapeutic Outcomes

Single Agent Daratumumab in Advanced Multiple Myeloma: Specific Healthcare Program in the Czech Republic

Prognostic Value of the Parameters of Myeloma Bone Disease Signaling in Patients with Newly Diagnosed Multiple Myeloma Treated with Proteasome Inhibitors

Assessment of the Parameters of Myeloma Bone Disease Signaling to the Extent of Skeletal Involvement, Bone Mineral Turnover and Activity of Multiple Myeloma

Multiple Myeloma and Bone Marrow Microenvironment Immunohistochemical Study of the Expression of 15 Proteins Related to Myeloma Bone Disease

Early Diagnosis of Multiple Myeloma - Project CRAB of Czech Myeloma Group(CMG)

Subcutaneous and Intravenous Bortezomib in Multiple Myeloma Patients Has Similar Response Rates and Toxicity Profile with No Difference in the Incidence of Peripheral Neuropathy: Report of the Czech Myeloma Group

Assessment of Signalling Pathways in Myeloma Bone Disease Using Selected Parameters of Bone Marow Microenvironment

The Use Of Selected Parameters Of Bone Microenvironment For The Assessment Of Skeletal Involvement and Activity In Multiple Myeloma and Monoclonal Gammopathy Of Undetermined Significance

Combined Measurement of Plasma Cell Proliferation and Apoptosis in Multiple Myeloma.

Long-Term Outcomes of Autologous Transplantation in Multiple Myeloma: Benefit from the Newer Drugs Used in the Relapsed Setting.

Angiotensin-I Converting Enzyme Inhibitors and the Survival of Patients with Multiple Myeloma Treated by Autologous Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only